Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cobimetinib

Cobimetinib Reactions 1704, p117 - 2 Jun 2018 Focal necrotising myopathy with dropped-head syndrome: case report A 72-year-old man developed focal necrotising myopathy with dropped-head syndrome following treatment with cobimetinib [route not stated]. The man, who had Parkinson’s disease and NRAS-mutated advanced melanoma, started receiving treatment with cobimetinib 60 mg/day, 3 weeks and 1 week off. His concurrent treatment included nivolumab, levodopa, unspecified monoamine oxidase inhibitor and anti-cholinergic agent. One month after initiation of cobimetinib treatment, he presented with incapsular pain and axial fatigue with cervical hypotonia. Subsequent laboratory investigation revealed a slight grade 1 liver enzyme elevation, more marked on the AST. Fifteen days later, a clinical reassessment revealed worsening of clinical symptoms. The cervical muscle strength was found to have decreased to 4/5. Laboratory test revealed increased level of CPK up to 1011 U/L (n < 308). Subsequent PET CT revealed intense uptake in the cervical muscles, which was not present on previous images 2.5 months earlier, before the start of cobimetinib. Consequently, a muscle biopsy of the pathological cervical muscles was performed with ultrasound guidance. Histological examination revealed some necrotic muscle fibers and focal regenerative basophilic fibers dispersed throughout the bundles, without pathological inflammation but with a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Cobimetinib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Cobimetinib

Abstract

Reactions 1704, p117 - 2 Jun 2018 Focal necrotising myopathy with dropped-head syndrome: case report A 72-year-old man developed focal necrotising myopathy with dropped-head syndrome following treatment with cobimetinib [route not stated]. The man, who had Parkinson’s disease and NRAS-mutated advanced melanoma, started receiving treatment with cobimetinib 60 mg/day, 3 weeks and 1 week off. His concurrent treatment included nivolumab, levodopa, unspecified monoamine oxidase inhibitor and...
Loading next page...
1
 
/lp/springer_journal/cobimetinib-jmaxibuSFf

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46760-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p117 - 2 Jun 2018 Focal necrotising myopathy with dropped-head syndrome: case report A 72-year-old man developed focal necrotising myopathy with dropped-head syndrome following treatment with cobimetinib [route not stated]. The man, who had Parkinson’s disease and NRAS-mutated advanced melanoma, started receiving treatment with cobimetinib 60 mg/day, 3 weeks and 1 week off. His concurrent treatment included nivolumab, levodopa, unspecified monoamine oxidase inhibitor and anti-cholinergic agent. One month after initiation of cobimetinib treatment, he presented with incapsular pain and axial fatigue with cervical hypotonia. Subsequent laboratory investigation revealed a slight grade 1 liver enzyme elevation, more marked on the AST. Fifteen days later, a clinical reassessment revealed worsening of clinical symptoms. The cervical muscle strength was found to have decreased to 4/5. Laboratory test revealed increased level of CPK up to 1011 U/L (n < 308). Subsequent PET CT revealed intense uptake in the cervical muscles, which was not present on previous images 2.5 months earlier, before the start of cobimetinib. Consequently, a muscle biopsy of the pathological cervical muscles was performed with ultrasound guidance. Histological examination revealed some necrotic muscle fibers and focal regenerative basophilic fibers dispersed throughout the bundles, without pathological inflammation but with a

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.